Werfen, a Barcelona, Spain-based manufacturer and distributor of Specialized Diagnostic instruments, related reagents, automation workcells, and data management solutions, acquired Immucor, a Norcross, Georgia, USA-based transfusion and transplant in vitro diagnostics company, from TPG.
The amount of the deal – expected to close during the first half of 2023 – is expected to be approximately US$2 billion. The acquisition will allow Werfen to expand its portfolio of Specialized Diagnostics solutions for hospitals and clinical laboratories. Upon completion of this acquisition, and based on 2021 figures, Werfen will surpass €2.2 billion in revenue, with seven technology centers, close to 7,000 employees worldwide, and a direct presence in 30 countries and more than 100 territories through distributors.
Led by Avi Pelossof, CEO, Immucor is a provider of transfusion and transplantation diagnostic products worldwide.
Led by CEO Carlos Pascual, Werfen is a developer, manufacturer and distributor of Specialized Diagnostic instruments, related reagents, automation workcells, and data management solutions for use primarily in hospitals and independent clinical laboratories. Its business units include Hemostasis, Acute Care Diagnostics, Autoimmunity, and Original Equipment Manufacturing (OEM).
FinSMEs
07/11/2022